Active Ingredient: GLYCOPYRRONIUM
In a thorough QT crossover study of 73 healthy subjects, a single supratherapeutic dose of 400 µg (8 times the standard clinical dose) was evaluated. The maximum mean placebo-corrected QTcF change (ΔΔQTcF) was only 2.97 ms (upper 90% CI: 4.80 ms), well below the 10 ms regulatory threshold. A slight, transient bradycardic effect was observed (max −5.87 bpm at 5 hours), but with no clinically relevant impact on blood pressure or other ECG intervals.
https://doi.org/10.5414/cp202096